Adoptive Transfer of mRNA-Transfected T Cells Redirected against Diabetogenic CD8 T Cells Can Prevent Diabetes.

Chimeric major histocompatibility complex (MHC) molecules supplemented with T cell receptor (TCR) signaling motifs function as activation receptors and can redirect gene-modified T cells against pathogenic CD8 T cells. We have shown that β2 microglobulin (β2m) operates as a universal signaling component of MHC-I molecules when fused with the CD3-ζ chain. Linking the H-2Kd-binding insulin B chain peptide insulin B chain, amino acids 15-23 (InsB15-23) to the N terminus of β2m/CD3-ζ, redirected polyclonal CD8 T cells against pathogenic CD8 T cells in a peptide-specific manner in the non-obese diabetic (NOD) mouse. Here, we describe mRNA electroporation for delivering peptide/β2m/CD3-ζ genes to a reporter T cell line and purified primary mouse CD8 T cells. The peptide/β2m/CD3-ζ products paired with endogenous MHC-I chains and transmitted strong activation signals upon MHC-I cross-linking. The reporter T cell line transfected with InsB15-23/β2m/CD3-ζ mRNA was activated by an InsB15-23-H-2Kd-specific CD8 T cell hybrid only when the transfected T cells expressed H-2Kd. Primary NOD CD8 T cells expressing either InsB15-23/β2m/CD3-ζ or islet-specific glucose-6-phosphatase catalytic subunit-related protein, amino acids 206-214 (IGRP206-214)/β2m/CD3-ζ killed their respective autoreactive CD8 T cell targets in vitro. Furthermore, transfer of primary CD8 T cells transfected with InsB15-23/β2m/CD3-ζ mRNA significantly reduced insulitis and protected NOD mice from diabetes. Our results demonstrate that mRNA encoding chimeric MHC-I receptors can redirect effector CD8 against diabetogenic CD8 T cells, offering a new approach for the treatment of type 1 diabetes.

[1]  Jan Engberg,et al.  Chimeric β2 microglobulin/CD3ζ polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8+ T cells , 2003 .

[2]  L. Wen,et al.  Immunotargeting of insulin reactive CD8 T cells to prevent diabetes. , 2010, Journal of autoimmunity.

[3]  U. Şahin,et al.  Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. , 2006, Blood.

[4]  N. Shastri,et al.  Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Roopenian,et al.  Identification of a CD8 T Cell That Can Independently Mediate Autoimmune Diabetes Development in the Complete Absence of CD4 T Cell Helper Functions1 , 2000, The Journal of Immunology.

[6]  J. Engberg,et al.  Chimeric beta2 microglobulin/CD3zeta polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8(+) T cells. , 2003, International Immunology.

[7]  G. Gross,et al.  Messenger RNA encoding constitutively active Toll‐like receptor 4 enhances effector functions of human T cells , 2015, Clinical and experimental immunology.

[8]  D. Faustman,et al.  The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies , 2009, Journal of Molecular Medicine.

[9]  B. Levine,et al.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. , 2010, Cancer research.

[10]  Alon Margalit,et al.  Membrane-anchored beta 2-microglobulin stabilizes a highly receptive state of MHC class I molecules. , 2005, Journal of immunology.

[11]  A. Purcell,et al.  Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. , 2006, The Journal of clinical investigation.

[12]  L. Wen,et al.  Activation of Insulin-Reactive CD8 T-Cells for Development of Autoimmune Diabetes , 2009, Diabetes.

[13]  N. Shastri,et al.  Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Park,et al.  Prevalent CD8(+) T cell response against one peptide/MHC complex in autoimmune diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  F. Wong,et al.  Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. , 2002, Immunity.

[17]  D. Finegood,et al.  Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. , 2003, The Journal of clinical investigation.

[18]  P. Santamaria,et al.  CD8+ T cells in type 1 diabetes. , 2008, Advances in immunology.

[19]  P. Nguyen,et al.  Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes , 2003, Gene Therapy.

[20]  E. Sercarz,et al.  MHC Class I-Restricted Determinants on the Glutamic Acid Decarboxylase 65 Molecule Induce Spontaneous CTL Activity1 , 2001, The Journal of Immunology.

[21]  C. Boitard,et al.  Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Quinn,et al.  Dominant CTL-inducing epitopes on GAD65 are adjacent to or overlap with dominant Th-inducing epitopes. , 2007, Clinical immunology.

[23]  F. Wong,et al.  A reproducible method for the expansion of mouse CD8 + T lymphocytes , 2015, Journal of immunological methods.

[24]  E. Gilboa,et al.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. , 2000, Cancer research.

[25]  L. Harrison,et al.  Autoimmunity to Both Proinsulin and IGRP Is Required for Diabetes in Nonobese Diabetic 8.3 TCR Transgenic Mice1 , 2008, The Journal of Immunology.

[26]  J. Shabanowitz,et al.  Identification of the β cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. van Endert,et al.  Identification of naturally processed HLA-A2--restricted proinsulin epitopes by reverse immunology. , 2005, Diabetes.

[28]  L. Wen,et al.  Developing a Novel Model System to Target Insulin‐Reactive CD8 T Cells , 2008, Annals of the New York Academy of Sciences.

[29]  C. Janeway,et al.  Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2Kd that stimulates CD8 T cells in insulin-dependent diabetes mellitus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Janeway,et al.  Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in insulin-dependent diabetes mellitus. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Rosenberg,et al.  Signaling through MHC in transgenic mice generates a population of memory phenotype cytolytic cells that lack TCR. , 2003, Blood.

[32]  F. Wong,et al.  Human CD8 Responses to a Complete Epitope Set from Preproinsulin: Implications for Approaches to Epitope Discovery , 2008, Journal of Clinical Immunology.

[33]  H. Festenstein,et al.  Interspecies exchange of β2-microglobulin and associated MHC and differentiation antigens , 2004, Immunogenetics.

[34]  F. Wong,et al.  Selective immunotargeting of diabetogenic CD4 T cells by genetically redirected T cells , 2014, Immunology.

[35]  Y. Carmi,et al.  Induction of Antitumor Immunity by CTL Epitopes Genetically Linked to Membrane-Anchored β2-Microglobulin1 , 2006, The Journal of Immunology.

[36]  J. Drijfhout,et al.  CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. , 2008, The Journal of clinical investigation.

[37]  G. Schuler,et al.  Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer , 2009, Gene Therapy.

[38]  M. Dolz,et al.  CD8+ T-Cell Responses Identify β-Cell Autoimmunity in Human Type 1 Diabetes , 2007, Diabetes.

[39]  C. Janeway,et al.  CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells , 1996, The Journal of experimental medicine.

[40]  S. Almo,et al.  Compensatory Mechanisms Allow Undersized Anchor-Deficient Class I MHC Ligands To Mediate Pathogenic Autoreactive T Cell Responses , 2014, The Journal of Immunology.

[41]  C. Janeway,et al.  Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library , 1999, Nature Medicine.

[42]  Irene Jarchum,et al.  In Vivo Cytotoxicity of Insulin-Specific CD8+ T-Cells in HLA-A*0201 Transgenic NOD Mice , 2007, Diabetes.

[43]  Alon Margalit,et al.  Membrane-Anchored β2-Microglobulin Stabilizes a Highly Receptive State of MHC Class I Molecules1 , 2005, The Journal of Immunology.

[44]  Z. Eshhar,et al.  Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. , 2016, Annual review of pharmacology and toxicology.

[45]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes , 2005 .

[46]  M. Atkinson,et al.  Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients , 2012, The Journal of experimental medicine.

[47]  S. Tafuro,et al.  Progression of autoimmune diabetes driven by avidity maturation of a T-cell population , 2000, Nature.

[48]  S. Richardson,et al.  Analysis of islet inflammation in human type 1 diabetes , 2009, Clinical and experimental immunology.

[49]  G. Gross,et al.  Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants , 2016, Journal of immunotherapy.

[50]  D. Serreze,et al.  The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice , 2005, Immunological reviews.

[51]  L. Pedersen,et al.  The interaction of beta 2‐microglobulin (β2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse β2m , 1995, European journal of immunology.

[52]  Bingye Han,et al.  Individual Nonobese Diabetic Mice Exhibit Unique Patterns of CD8+ T Cell Reactivity to Three Islet Antigens, Including the Newly Identified Widely Expressed Dystrophia Myotonica Kinase1 , 2004, The Journal of Immunology.